Currency in USD
Last close As at 17/03/2023
USD0.69
▲ −0.04 (−5.48%)
Market capitalisation
USD11m
Research: Healthcare
Context Therapeutics has presented a recap of key highlights of 2022 as well as strategic priorities and operational guidance for 2023. The past year saw the company making progress in advancing both of its pipeline assets, presenting encouraging preliminary data from its ongoing studies in metastatic breast cancer (SMILE trial) and endometrial cancer (OATH trial), signing a collaboration agreement with the Menarini Group (ELONA trial) and finalizing its CNDL6 clinical candidate (CTIM-76). Tight capital markets and bearish investor sentiment drove Context to trim non-essential R&D expenses, extending the cash runway into Q124, past several development milestones. We see the additional data readouts from the Phase II OATH (expected in mid-2023) and SMILE (Q423) trials and Phase Ib ELONA trial (Q423) as key upcoming catalysts for Context.
Context Therapeutics |
A catalyst-rich period ahead |
Business update |
Pharma and biotech |
6 January 2023 |
Share price performance Business description
Analysts
Context Therapeutics is a research client of Edison Investment Research Limited |
Context Therapeutics has presented a recap of key highlights of 2022 as well as strategic priorities and operational guidance for 2023. The past year saw the company making progress in advancing both of its pipeline assets, presenting encouraging preliminary data from its ongoing studies in metastatic breast cancer (SMILE trial) and endometrial cancer (OATH trial), signing a collaboration agreement with the Menarini Group (ELONA trial) and finalizing its CNDL6 clinical candidate (CTIM-76). Tight capital markets and bearish investor sentiment drove Context to trim non-essential R&D expenses, extending the cash runway into Q124, past several development milestones. We see the additional data readouts from the Phase II OATH (expected in mid-2023) and SMILE (Q423) trials and Phase Ib ELONA trial (Q423) as key upcoming catalysts for Context.
Year end |
Revenue |
PBT* ($m) |
EPS* |
DPS |
P/E |
Yield |
12/20 |
0.0 |
(3.2) |
(9.28) |
0.0 |
N/A |
N/A |
12/21 |
0.0 |
(10.6) |
(3.74) |
0.0 |
N/A |
N/A |
12/22e |
0.0 |
(18.1) |
(1.13) |
0.0 |
N/A |
N/A |
12/23e |
0.0 |
(27.4) |
(1.72) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalized, excluding exceptional items.
The past year was marked by several key advancements in the company’s therapeutic pipeline, including selection of CTIM-76 as the CLDN6 clinical candidate, preliminary data readouts from two ONA-XR Phase II trials and the signing of the collaboration deal with Menarini to study ONA-XR in combination with elascestrant, a class-leading oral selective estrogen receptor degrader (SERD). CTIM-76, currently undergoing Investigational New Drug (IND)-enabling studies (target filing timeline of Q124), has demonstrated over 1,000x selectivity for CLDN6 versus CLDN9 and 28x more potency than a competing bispecific T-cell engager (BiTE) in in-vitro studies and holds promise as a new class of therapeutics.
For ONA-XR, preliminary data from the OATH trial were particularly encouraging, demonstrating a four-month progression free survival (PFS) of 77.7% and a 12-month PFS of 33%, which compares favorably to the 3.8-month median PFS demonstrated by the chemotherapy arm in the Phase III KEYNOTE-775 trial. Early data from the SMILE trial were also positive, delivering a four-month PFS of 44% in comparison to a median PFS of approximately two months in a similar population in the EMERALD Phase III trial. We note, however, that the small cohort size of these initial studies limits absolute comparability to these large pivotal trials.
We also see the collaboration agreement with Menarini as a key milestone of 2022, given that elacestrant delivered a 0.9-month PFS improvement over the standard of care (SoC) injectable SERD fulvestrant in the EMERALD Phase III trial, and holds the ability to replace the drug as the new SoC. Context asserts that a combination of elacestrant and ONA-XR can potentially improve survivability given the broader inhibition of hormone receptor signalling.
We anticipate 2023 to be a catalyst-rich year for Context, with data expected from all three ONA-XR studies. Tightened reins on operating expenses means that the cash situation remains comfortable for now, with the company well capitalized into Q124, past all key readouts.
|
|
Research: Consumer
Greggs reported a strong acceleration in revenue growth in Q422 as revenue from new initiatives, digital and evening trading complemented anticipated space growth and underlying growth. Value leadership continues to support volume growth and the company’s ability to pass on inflationary cost pressures. As Greggs enters the second full year of its five-year strategy, FY23 profit growth is expected to improve as newer initiatives mature, and following the suppression of FY22 profit by internal investment, cost inflation and the return of some costs to the income statement post the initial COVID outbreak. We trim our FY23 and FY24 estimates by 3%, primarily due to higher-than-expected cost inflation.
Get access to the very latest content matched to your personal investment style.